SCHEMBL3585848

SCHEMBL3585848

c1ccc2c(CCOC3CCCCC3N3CCOCC3)csc2c1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 6/20 0.68
SCN5A Q14524 6/20 0.68
OPRM1 P35372 4/20 0.44
OPRK1 P41145 4/20 0.44
HTR7 P34969 2/20 0.41
CHRNA7 P36544 1/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MTNR1A P48039 1/20 0.39
F10 P00742 1/20 0.36
CYP2A6 P11509 2/20 0.36
SLC6A4 P31645 2/20 0.35
SLC6A2 P23975 1/20 0.35
KCND2 Q9NZV8 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3585845 1.00 KCNA5 (0.68) KCNA5SCN5AOPRM1OPRK1HTR7
SCHEMBL2624918 1.00 KCNA5 (0.68) KCNA5SCN5AOPRM1OPRK1HTR7
Hydrochloric Acid SCHEMBL908544 0.99 KCNA5 (0.67) KCNA5SCN5AOPRM1OPRK1HTR7
Hydrochloric Acid SCHEMBL908545 0.99 KCNA5 (0.67) KCNA5SCN5AOPRM1OPRK1HTR7
SCHEMBL3593188 0.86 KCNA5 (0.70) KCNA5SCN5AOPRM1OPRK1
SCHEMBL2624920 0.86 KCNA5 (0.70) KCNA5SCN5AOPRM1OPRK1
SCHEMBL3593186 0.86 KCNA5 (0.70) KCNA5SCN5AOPRM1OPRK1
Hydrochloric Acid SCHEMBL908557 0.85 KCNA5 (0.69) KCNA5SCN5AOPRM1OPRK1
Hydrochloric Acid SCHEMBL908556 0.85 KCNA5 (0.69) KCNA5SCN5AOPRM1OPRK1
SCHEMBL12391697 0.81 KCNA5 (1.00) KCNA5SCN5ASLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029639-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2010-02-04 US claimed
US-7534790-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2009-05-19 US claimed
US-20080070911-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2008-03-20 US claimed
US-20070004718-A1 Ion channel modulating compounds and uses thereof CARDIOME PHAMA CORP. (CA) 2007-01-04 US claimed
US-7101877-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2006-09-05 US claimed
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2005-09-01 US claimed
US-20050020481-A1 Ion channel modulating compounds and uses thereof BAIN ALLAN I (CA) 2005-01-27 US claimed
EP-1422217-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2004-05-26 EP claimed
EP-1087934-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC (CA) 2004-02-25 EP claimed
US-20160089361-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CARDIOME PHARMA CORP (CA) 2016-03-31 US disclosed
US-20150099788-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CARDIOME PHARMA CORP (CA) 2015-04-09 US disclosed
EP-2468278-A1 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia Cardiome Pharma Corp. (CA) 2012-06-27 EP disclosed
EP-2462933-A1 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia Cardiome Pharma Corp. (CA) 2012-06-13 EP disclosed
US-20110207730-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-08-25 US disclosed
US-20070004718-A1 Ion channel modulating compounds and uses thereof CARDIOME PHAMA CORP. (CA) 2007-01-04 US disclosed
US-20050209307-A1 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics CARDIOME PHARMA CORP. (CA) 2005-09-22 US disclosed
EP-1422217-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2004-05-26 EP disclosed
EP-1087934-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC (CA) 2004-02-25 EP disclosed
EP-1087934-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF Nortran Pharmaceuticals Inc. (CA) 2001-04-04 EP disclosed
WO-1999050225-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC. (CA) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099788-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CYP2D6, KCNA6, CYP2A6 KCNA5 31/4885SCN5A 69/4885OPRM1 1067/4885
US-20110207730-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885OPRM1 189/4885
US-20050020481-A1 Ion channel modulating compounds and uses thereof TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885OPRM1 189/4885
US-20070004718-A1 Ion channel modulating compounds and uses thereof TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885OPRM1 189/4885
US-20050209307-A1 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics KCNH1, TRPV1, KCNH2 KCNA5 19/4885SCN5A 20/4885OPRM1 98/4885
US-20080070911-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885OPRM1 189/4885
US-20160089361-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CYP2D6, KCNA6, CYP2A6 KCNA5 31/4885SCN5A 69/4885OPRM1 1067/4885
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 21/4885SCN5A 46/4885OPRM1 176/4885
US-20100029639-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885OPRM1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.